The recent discovery of somatic activating mutations in the tyrosine kinase domain of the EGFR gene in the tumour brings new hope of improved ability to predict response to gefitinib (Lynch et al, 2004; Paez et al, 2004). This evidence concerns the gene EGFR and neoplasm.